SINGAPORE, Sept. 3, 2025 /PRNewswire/ — FUKU.AI, a Singapore-headquartered artificial intelligence recruitment platform operating on a SaaS business model, today announced that it has raised SGD 1.1 million in a pre-seed round from a family office and angel investors.

FUKU.AI Co-founders Kevin Gao & Kai Yang FUKU.AI Co-founders Kevin Gao & Kai Yang

The company officially launched its beta product in June 2025 and has since attracted over 190 SMEs as users, with a waitlist of more than 500 companies.

FUKU.AI was founded by Kevin Gao, a recruitment industry veteran, and Kai Yang, a Harvard-educated AI engineer recognized as the top computer science student under Nobel Prize winner Professor Geoffrey Hinton.

The FUKU.AI platform differentiates itself through a proprietary resume-matching discriminator model featuring deep contextual understanding and multi-channel candidate outreach powered by a large language model (LLM) assessment engine.

 "Small and medium-sized enterprises need affordable, efficient recruitment solutions tailored to attract PMET professionals in today’s fast evolving job market," said Kevin Gao, CEO of FUKU.AI. "Our SaaS platform delivers enterprise-grade capabilities at accessible costs, empowering SMEs to secure top talent competitively."

FUKU.AI plans to expand regionally to Malaysia, Hong Kong, Japan, and Australia, targeting $1 million in annual recurring revenue within the next year.

About FUKU.AI

Founded in 2025, FUKU.AI is an AI-powered recruitment platform headquartered in Singapore, dedicated to providing scalable and efficient hiring solutions for SMEs across Asia. Visit https://www.fuku.ai for more information or contact Eddie Ler, Chief Strategy Officer at eddie@fuku.ai

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Morphy Richards Announces Brand Strategy Upgrade, Followed by Launch of Several New Innovations

LONDON, April 16, 2024 /PRNewswire/ — Morphy Richards, a renowned brand known for…

HKBN Appoints Dr Gabriel Leung as Chief Executive Officer – Enterprise Solutions

HONG KONG, Nov. 1, 2024 /PRNewswire/ — HKBN Group ("HKBN" or the…

Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%

JINAN, China, Dec. 6, 2023 /PRNewswire/ — Qilu Pharmaceutical presented the latest…